Amgen Inc on Monday said it had reached a deal with British drugmaker GlaxoSmithKline to reacquire the sales rights to three of its products in 48 countries, including Australia as well as markets in Asia, South America and Europe.
The three Amgen drugs are the osteoporosis treatment Prolia; the related drug XGeva, used to prevent fractures in cancer that has spread to the bone, and Vectibix for advanced colorectal cancer.
The year isn’t even over yet, but venture fund Rock Health is reporting that venture investment in digital health has equaled 2014’s record of $4.3 billion. Digital health continues to account for about 7 percent of all venture funding, the San Francisco-based organization said.
“While skeptics may use the flatness of growth to question the attractiveness of the digital health industry, it’s important to keep in perspective what an incredible feat it was for 2015 to be on track with record-breaking 2014,” Rock Health said in its year-in-review, released Monday. “The steady amount of funding should calm any concerns of a bubble.”
The MACH37 Cyber Accelerator program lasts for 90 days and is composed of startups that are cultivated from the area’s best and brightest and they are instructed on the various facets of starting and sustaining a successful business. The first session was held in September of 2013 and since then there have been five classes and 29 new cyber security companies have been launched as a result.
AstraZeneca confirmed Monday morning that it is “exploring potential strategic options” with Acerta Pharma BV.
Acerta is a privately held biopharmaceutical company with offices in California and The Netherlands. Its lead product is an experimental blood cancer drug, called acalabrutinib, which is in late-stage clinical testing.
Amidst the rhetoric of Campaign 2016, the reality of escalating health costs, and the acceleration of consolidation across the industry, healthcare headlines in 2016 will highlight major changes that will reshape the future for the next decade and beyond.
Here’s the top 10 you can expect to read next year:
Gaithersburg-based biotech WellStat Therapeutics Corp. received Food and Drug Administration approval for Vistogard, an emergency treatment for an overdose of certain chemotherapy drugs, it was announced Friday.
It is the second FDA approval the company has received for one of its drugs this fall.
Prince William County is in a race to establish itself as the center of bioscience research and commercialization and it’s making progress. The county’s science accelerator, established two years ago, now has three companies and will add two more in the next few months. Prince William’s head of economic development, Jeff Kaczmarek, says the accelerator is aiming to be at full capacity by the end of next year, as more companies take up its 9,100 SF, which is the only commercially available wet lab space in the region.
Dr Martine Rothblatt and Cyndi Lauper were the recipients of this year’s Billie Jean King Leadership Initiative (BJKLI) awards on Wednesday night.
The tennis legend launched the non-profit BJKLI in 2014 with her partner, Ilana Kloss, to promote and celebrate inclusive leadership. This year’s awards gala, in partnership with Teneo, took place Wednesday night at World Trade Center 4 in New York.
AstraZeneca and its global biologics research and development arm, MedImmune, today announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome – research into all proteins that are secreted by a cell or that are exposed to the outside of the cell from within the cell membrane.
Although the University System of Maryland, at its core, is a collection of 12 colleges, new Chancellor Bob Caret says he sees it as a business — a business that the state needs to invest in. Caret said that for every $1 the state spends on USM, he can bring the state back $6.
